Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke

Cunningham CJ., Redondo-Castro E., Allan SM.

Narrative Review on Stroke Research, Chronic Inflammation, published in J Cereb Blood Flow Metab (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Cereb Blood Flow Metab (2018)
Reported sample size
—
Source database
Europe PMC
PMID
29768965
PMCID
PMC6077926
DOI
10.1177/0271678x18776802
Citations
180

Abstract (original English)

Mesenchymal stem cells (MSCs) hold great potential as a regenerative therapy for stroke, leading to increased repair and functional recovery in animal models of cerebral ischaemia. While it was initially hypothesised that cell replacement was an important mechanism of action of MSCs, focus has shifted to their paracrine actions or the so called "bystander" effect. MSCs secrete a wide array of growth factors, chemokines, cytokines and extracellular vesicles, commonly referred to as the MSC secretome. There is evidence suggesting the MSC secretome can promote repair through a number of mechanisms including preventing cell apoptosis, modulating the inflammatory response and promoting endogenous repair mechanisms such as angiogenesis and neurogenesis. In this review, we will discuss the in vitro approaches currently being employed to drive the MSC secretome towards a more anti-inflammatory and regenerative phenotype. We will then examine the role of the secretome in promoting repair and improving recovery in preclinical models of cerebral ischaemia.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansBrain IschemiaInflammationMesenchymal Stem Cell TransplantationCell Culture TechniquesNeovascularization, PhysiologicStrokeNeurogenesis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research